Fig. 2: MOAlmanac increases the number of nominated clinically relevant molecular features in four retrospective cohorts.

MOAlmanac was benchmarked against PHIAL and TARGET using molecular profiles of 110 patients with metastatic melanoma, 150 patients with mCRPC, 100 patients with KIRP, and 59 patients with OS. a, MOAlmanac increased the number of patients with a clinically relevant somatic variant or copy number alteration from 295 to 365 relative to results from PHIAL; patients are aligned across feature types vertically. b, Molecular features not routinely used in clinical sequencing were used to expand translational hypotheses. c, Counts of clinically relevant somatic variants or copy number alterations by ontology. Amp, amplification; del, deletion. d, Counts of clinically relevant molecular features from expanded feature types. WGD, whole-genome doubling. Data are available as source data.